152 related articles for article (PubMed ID: 37541451)
1. Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors.
Lanzi C; Arrighetti N; Pasquali S; Cassinelli G
Biochem Pharmacol; 2023 Sep; 215():115727. PubMed ID: 37541451
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
3. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
4. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas.
Sápi Z; Papp G; Szendrői M; Pápai Z; Plótár V; Krausz T; Fletcher CD
Genes Chromosomes Cancer; 2016 Oct; 55(10):786-802. PubMed ID: 27223121
[TBL] [Abstract][Full Text] [Related]
6. Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma.
Del Savio E; Maestro R
Cells; 2022 Aug; 11(17):. PubMed ID: 36078034
[TBL] [Abstract][Full Text] [Related]
7. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
[TBL] [Abstract][Full Text] [Related]
8. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
[TBL] [Abstract][Full Text] [Related]
9. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma.
Papp G; Changchien YC; Péterfia B; Pecsenka L; Krausz T; Stricker TP; Khoor A; Donner L; Sápi Z
Mod Pathol; 2013 Mar; 26(3):393-403. PubMed ID: 23174932
[TBL] [Abstract][Full Text] [Related]
10. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
Kohashi K; Yamamoto H; Kumagai R; Yamada Y; Hotokebuchi Y; Taguchi T; Iwamoto Y; Oda Y
Mod Pathol; 2014 Jun; 27(6):832-9. PubMed ID: 24287458
[TBL] [Abstract][Full Text] [Related]
11. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.
Schaefer IM; Agaimy A; Fletcher CD; Hornick JL
Mod Pathol; 2017 Apr; 30(4):539-548. PubMed ID: 28084340
[TBL] [Abstract][Full Text] [Related]
12. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
13. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
14. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
16. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
Le Quang M; Ranchère-Vince D; Le Loarer F
Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
[TBL] [Abstract][Full Text] [Related]
17. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
18. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
19. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.
Le Loarer F; Zhang L; Fletcher CD; Ribeiro A; Singer S; Italiano A; Neuville A; Houlier A; Chibon F; Coindre JM; Antonescu CR
Genes Chromosomes Cancer; 2014 Jun; 53(6):475-86. PubMed ID: 24585572
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Therapy for Epithelioid Sarcoma.
Rothbart SB; Baylin SB
Cell; 2020 Apr; 181(2):211. PubMed ID: 32302562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
